Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $272.90, for a total value of $818,700.00. Following the sale, the insider directly owned 134,643 shares of the company’s stock, valued at $36,744,074.70. The trade was a 2.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, June 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $218.43, for a total transaction of $655,290.00.
• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The stock was sold at an average price of $202.84, for a total transaction of $335,091.68.
• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The stock was sold at an average price of $203.69, for a total transaction of $693,564.45.
• On Monday, April 27th, Solomon Moshkevich sold 2,182 shares of Natera stock. The shares were sold at an average price of $204.10, for a total transaction of $445,346.20.

Natera Price Performance

Shares of NTRA opened at $283.80 on Tuesday. The company has a market capitalization of $40.64 billion, a PE ratio of -174.11 and a beta of 1.51. Natera, Inc. has a one year low of $131.81 and a one year high of $288.04. The company’s fifty day moving average price is $221.45 and its 200 day moving average price is $217.64.

Institutional Trading of Natera

A number of institutional investors and hedge funds have recently modified their holdings of the company. Reflection Asset Management acquired a new position in shares of Natera in the fourth quarter valued at $29,000. Palladiem LLC acquired a new stake in Natera during the fourth quarter worth $31,000. Horizon Investments LLC acquired a new stake in Natera during the third quarter worth $32,000. International Assets Investment Management LLC increased its holdings in Natera by 132.9% in the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after buying an additional 97 shares during the period. Finally, Bank of Jackson Hole Trust increased its holdings in Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after buying an additional 83 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Robert W. Baird set a $265.00 price objective on Natera in a research report on Friday, May 8th. UBS Group set a $260.00 target price on Natera in a report on Wednesday, June 24th. The Goldman Sachs Group began coverage on Natera in a research report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price target on the stock. Sanford C. Bernstein started coverage on Natera in a report on Friday, June 26th. They set an “outperform” rating and a $310.00 price target for the company. Finally, Wells Fargo & Company increased their price objective on Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and a consensus target price of $262.00.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.